research use only

EN4 Myc inhibitor

Name: EN4
Brand: Selleck Chemicals
SKU: S9807
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S9807

EN4, a covalent ligand that targets cysteine 171 (C171) of MYC, is selective for c-MYC over N-MYC and L-MYC. This compound inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.

Chemical Structure

Molecular Weight: 416.47

Jump to

Quality Control

Batch: S980701 DMSO]83 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 98.82%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS
Datasheet

98.82

Related Targets	CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase
Other Myc Inhibitors	MYCi975 10058-F4 10074-G5 MYCi361 APTO-253 Mycro 3 Cpd. 37 ML327 MYCMI-6 BTYNB

Solubility

In vitro
Batch:

DMSO : 83 mg/mL (199.29 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.150mg/ml (9.96mM)	Taking the 1 mL working solution as an example, add 50 μL of 83 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.510mg/ml (1.22mM)	Taking the 1 mL working solution as an example, add 50 μL of 10.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	416.47	Formula	C₂₅H₂₄N₂O₄	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1197824-15-9	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CCOC1=CC=C(OC2=C(NC(=O)C3=CC=C(CNC(=O)C=C)C=C3)C=CC=C2)C=C1

Mechanism of Action

Targets/IC₅₀/Ki	MYC
In vitro	EN4 directly targets MYC in cells, reduces MYC and MAX thermal stability, inhibits MYC transcriptional activity, downregulates multiple MYC transcriptional targets, and impairs tumorigenesis. This compound treatment significantly impairs 231MFP breast cancer cell proliferation in a dose- and time-dependent manner. It impairs the cell survival of MYC transformed mammary epithelial MCF10A cells, but not parental MCF10A cells that are not dependent on MYC.
In vivo	EN4 treatment initiated after establishment of a 231MFP breast tumor xenograft in immune-deficient mice also significantly attenuates tumor growth in vivo.
References	[1] https://pubmed.ncbi.nlm.nih.gov/32966806/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04820361	Recruiting	Pain Neuropathic	Albina Nowak MD\|Swiss National Science Foundation\|University of Zurich	July 7 2022	Not Applicable
NCT05521737	Recruiting	Electroacupuncture\|Acupuncture\|Diabetic Polyneuropathy\|Diabetic Peripheral Neuropathy\|Diabetic Peripheral Neuropathic Pain\|Nerve Conduction	Instituto Mexicano del Seguro Social\|National Polytechnic Institute Mexico\|Instituto Nacional de Salud Publica Mexico\|Escuela Superior de Medicina Instituto Politécnico Nacional\|Escuela Nacional de Medicina y Homeopatía Instituto Politécnico Nacional\|Universidad Nacional Autonoma de Mexico\|Facultad de Estudios Superiores Iztacala Universidad Nacional Autónoma de Mexico\|Facultad de Estudios Superiores Zaragoza Universidad Nacional Autónoma de Mexico\|Facultad de Medicina UNAM	November 1 2021	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):